JOINT FILING AGREEMENTJoint Filing Agreement • November 21st, 2022 • Dialectic Capital Management, Lp • In vitro & in vivo diagnostic substances
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Achieve Life Sciences, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby execute this Agreement.
